<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00977262</url>
  </required_header>
  <id_info>
    <org_study_id>NL2800108109</org_study_id>
    <nct_id>NCT00977262</nct_id>
  </id_info>
  <brief_title>Postprandial Inflammation and Fatty Acids</brief_title>
  <acronym>PIFA</acronym>
  <official_title>Effects of Fatty Acids on Postprandial Inflammatory Response of Healthy Obese and Type 2 Diabetic Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wageningen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to elucidate the acute effects of an oral intake of either saturated,
      monounsaturated or polyunsaturated fatty acids on peripheral blood mononuclear cells (PBMC)
      whole genome expression of obese and type 2 diabetic obese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consumption of high-fat diets can lead to postprandial dyslipidemia, impairment of
      endothelial function, activation of immune cells and changes in gene expression profiles of
      immune cells such as peripheral blood mononuclear cells (PBMC). Recently it was shown that
      postprandial gene expression profiles of PBMC and plasma triglyceride (TG) and free fatty
      acid (FFA) responses are dependent on the type of dietary fat consumed (i.e. saturated,
      monounsaturated and polyunsaturated). Since obese and diabetic subjects usually are in a
      pro-inflammatory state and have dyslipidemia and endothelial dysfunction we are interested in
      the effect of different fatty acids in a high load on the PBMC gene expression profiles,
      plasma cytokine profiles and endothelial function of these subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PBMC gene expression profiles</measure>
    <time_frame>0, 2, 4 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PBMC inflammatory response capacity</measure>
    <time_frame>0, 2, 4 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>0, 2, 4 hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Diabetes Type 2</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Healthy control subjects, High saturated fat shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control subjects, High Monounsaturated fat shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control subjects, High Polyunsaturated fat shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy obese subjecs, High saturated fat shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy obese subjects, High monounsaturated fat shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy obese subjects, High polyunsaturated fat shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese diabetes type 2 subjects, High Saturated fat shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese diabetes type 2 subjects, High Monounsaturated fat shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese diabetes type 2 subjects, High polyunsaturated fat shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High saturated fat shake</intervention_name>
    <description>milkshake containing 95 gram of fat, high percentage of saturated fat</description>
    <arm_group_label>Healthy control subjects, High saturated fat shake</arm_group_label>
    <arm_group_label>Healthy obese subjecs, High saturated fat shake</arm_group_label>
    <arm_group_label>Obese diabetes type 2 subjects, High Saturated fat shake</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High monounsaturated fat shake</intervention_name>
    <description>milkshake containing 95 gram of fat, high percentage of monounsaturated fat</description>
    <arm_group_label>Healthy control subjects, High Monounsaturated fat shake</arm_group_label>
    <arm_group_label>Healthy obese subjects, High monounsaturated fat shake</arm_group_label>
    <arm_group_label>Obese diabetes type 2 subjects, High Monounsaturated fat shake</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High polyunsaturated fat shake</intervention_name>
    <description>milkshake containing 95 gram of fat, high percentage polyunsaturated fat</description>
    <arm_group_label>Healthy control subjects, High Polyunsaturated fat shake</arm_group_label>
    <arm_group_label>Healthy obese subjects, High polyunsaturated fat shake</arm_group_label>
    <arm_group_label>Obese diabetes type 2 subjects, High polyunsaturated fat shake</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For all participants:

          -  male gender

          -  50-70 yrs

        For diabetic patients only:

          -  BMI &gt;30 kg/m2

          -  Well-controlled diabetes: fasting plasma glucose concentration must be &lt;10.0 mmol/l at
             the time of screening.

          -  Must be on sulphonylurea- or metformin therapy for at least 6 months with a constant
             dose for at least two months, or on dietary treatment for at least 6 months2.

        For obese controls only:

          -  BMI &gt; 30 kg/m2

          -  normoglycemic according to WHO criteria (OGTT, fasting blood glucose&lt; 7 mmol/L, after
             2 hr &lt;7.8mmol/L)

        For lean controls only:

          -  BMI 18-25 kg/m2

          -  normoglycemic according to WHO criteria (OGTT, fasting blood glucose&lt; 7 mmol/L, after
             2 hr &lt;7.8mmol/L)

        Exclusion Criteria:

        For all participants:

          -  Female gender

          -  Age below 50 or above 70 years

          -  Hemoglobin levels &lt;8.4 mmol/L

          -  Allergic to cow milk or dairy products

          -  Allergic to fish oil

          -  Vegetarian

          -  Tobacco smoker

          -  Current or recent (&lt;4 weeks) use of fish oil supplements or more then four times
             fish/week; 24.35 g of EPA-DHA of fish per month (800 mg/day) as judged by the
             questionnaire.

          -  Received inoculations within 2 months of starting the study or planned to during the
             study

          -  Donated or intended to donate blood from 2 months before the study till two months
             after the study

          -  Unstable body weight (weight gain or loss &gt; 3 kg in the past three months)

          -  Medical condition that can interfere with the study outcome (i.e. cardiovascular
             disease, gastrointestinal disease, renal dysfunction)

          -  Use of medications know to interfere with glucose homeostasis (i.e. corticosteroids)

          -  abuse of drugs and/or alcohol

          -  participation in another biomedical study within 1 month before the first screening
             visit

        For obese, type 2 diabetic subjects only:

          -  severe diabetes which requires application of insulin

          -  diabetes-related complications

        For obese subjects and lean controls only:

          -  hyperglycemic according to WHO criteria (OGTT, fasting blood glucose &gt;6.0mM, after 2
             hr&gt;11mM)

          -  systolic blood pressure &gt;160 mmHg or diastolic blood pressure &gt; 100 mmHg

          -  Urinary glucose concentrations (&gt;0.25 g/l)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Muller, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Chair Department of Human Nutrition NMG group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lydia A Afman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior scientist department Human Nutrition Wageningen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wageningen University, Division of Human Nutrition</name>
      <address>
        <city>Wageningen</city>
        <state>Gelderland</state>
        <zip>6700 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wageningen University, Division of Human Nutrition</name>
      <address>
        <city>Wageningen</city>
        <zip>6700 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2009</study_first_posted>
  <last_update_submitted>April 20, 2010</last_update_submitted>
  <last_update_submitted_qc>April 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Wageningen University, Division of Human Nutrition</name_title>
    <organization>Wageningen University</organization>
  </responsible_party>
  <keyword>fatty acids</keyword>
  <keyword>peripheral blood mononuclear cells</keyword>
  <keyword>inflammation</keyword>
  <keyword>nutrigenomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

